Teva Pharmaceutical Industries (TEVA) Return on Invested Capital (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Return on Invested Capital for 18 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.

• Quarterly Return on Invested Capital rose 1.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY) and the FY2025 annual result came in at 0.01%, up 2.0% from the prior year.
• Return on Invested Capital declined to 0.01% in Q1 2026 per TEVA's latest filing, from 0.01% in the prior quarter.
• Over the last five years, Return on Invested Capital for TEVA reached as high as 0.01% in Q4 2025 and fell as low as 0.0% in Q4 2022.
• A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2022 — Return on Invested Capital changed 0 bps — and 2025, when it advanced 1 bps.
• Year by year, Return on Invested Capital stood at 0.0% in 2022, then soared by 132 bps to 0.0% in 2023, then slumped by 238 bps to 0.0% in 2024, then surged by 1073 bps to 0.01% in 2025, then slipped by 25 bps to 0.01% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.01%, 0.01%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.